A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine; Cyclophosphamide; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 20 Apr 2021 Biomarkers information updated
- 20 Jun 2011 Preliminary results published in the Journal of Clinical Oncology.
- 07 Nov 2008 Updated from ClinicalTrials.gov record.